Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 2/2024

24-02-2024 | Acute Liver Failure | Guidelines

Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update

Authors: Yimin Mao, Shiwu Ma, Chenghai Liu, Xiaoyan Liu, Minghua Su, Dongliang Li, Yiling Li, Gongying Chen, Jun Chen, Jinjun Chen, Jingmin Zhao, Xiaoyan Guo, Jieting Tang, Yuzheng Zhuge, Qing Xie, Wen Xie, Rongtao Lai, Dachuan Cai, Qingxian Cai, Yang Zhi, Xiaoyun Li, the Technology Committee on DILI Prevention, Management, Chinese Medical Biotechnology Association; Study Group on Drug-Induced Liver Disease, Chinese Society of Hepatology, Chinese Medical Association

Published in: Hepatology International | Issue 2/2024

Login to get access

Abstract

Drug-induced liver injury (DILI) is an important adverse drug reaction that can lead to acute liver failure or even death in severe cases. Currently, the diagnosis of DILI still follows the strategy of exclusion. Therefore, a detailed history taking and a thorough and careful exclusion of other potential causes of liver injury is the key to correct diagnosis. This guideline was developed based on evidence-based medicine provided by the latest research advances and aims to provide professional guidance to clinicians on how to identify suspected DILI timely and standardize the diagnosis and management in clinical practice. Based on the clinical settings in China, the guideline also specifically focused on DILI in chronic liver disease, drug-induced viral hepatitis reactivation, common causing agents of DILI (herbal and dietary supplements, anti-tuberculosis drugs, and antineoplastic drugs), and signal of DILI in clinical trials and its assessment.
Appendix
Available only for authorised users
Literature
1.
Li X, Tang J, Mao Y. Incidence and risk factors of drug-induced liver injury. Liver Int. 2022;42:1999–2014PubMedCrossRef
2.
Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36:451–455PubMedCrossRef
3.
Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–1425PubMedCrossRef
4.
De Valle MB, Av Klinteberg V, Alem N, Olsson R, Björnsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2006;24:1187–1195PubMedCrossRef
5.
Andrade RJ, Lucena MI, Fernández MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512–521PubMedCrossRef
6.
Vega M, Verma M, Beswick D, et al. The incidence of drug- and herbal and dietary supplement-induced liver injury: preliminary findings from gastroenterologist-based surveillance in the population of the state of delaware. Drug Saf. 2017;40:783–787PubMedPubMedCentralCrossRef
7.
Suk KT, Kim DJ, Kim CH, et al. A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol. 2012;107:1380–1387PubMedCrossRef
8.
Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced liver injury in Mainland China. Gastroenterology. 2019;156:2230–2241PubMedCrossRef
9.
Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol. 2007;102:558–562PubMedCrossRef
10.
Breu AC, Patwardhan VR, Nayor J, et al. A multicenter study into causes of severe acute liver injury. Clin Gastroenterol Hepatol. 2019;17:1201–1203PubMedCrossRef
11.
Chang B, Li B, Huang A, et al. Changes of four common non-infectious liver diseases for the hospitalized patients in Beijing 302 hospital from 2002 to 2013. Alcohol. 2016;54:61–65PubMedCrossRef
12.
Tujios SR, Lee WM. Acute liver failure induced by idiosyncratic reaction to drugs: challenges in diagnosis and therapy. Liver Int. 2018;38:6–14PubMedCrossRef
13.
14.
Mao Y. HepaTox: a professional website that promotes clincial and translational research of DILI in China. Gan Zang. 2014;8:575–576
15.
Low EXS, Zheng Q, Chan E, Lim SG. Drug induced liver injury: east versus west—a systematic review and meta-analysis. Clin Mol Hepatol. 2020;26:142–154PubMedCrossRef
16.
Marzuki OA, Fauzi ARM, Ayoub S, Kamarul IM. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Singap Med J. 2008;49:688–693
17.
Chirapongsathorn S, Sukeepaisarnjaroen W, Treeprasertsuk S, et al. Characteristics of drug-induced liver injury in chronic liver disease: results from the Thai Association for the Study of the Liver (THASL) DILI Registry. J Clin Transl Hepatol. 2023;11:88–96PubMed
18.
Teo DCH, Ng PSL, Tan SH, et al. Drug-induced liver injury associated with complementary and alternative medicine: a review of adverse event reports in an Asian community from 2009 to 2014. BMC Complement Altern Med. 2016;16:192PubMedPubMedCentralCrossRef
19.
Huang Y-S, Tseng S-Y, Chen W-W, et al. Clinical characteristics and outcomes of drug-induced liver injury in Taiwan: with emphasis on the impact of chronic hepatitis B infection. J Chin Med Assoc. 2022;85:286–294PubMedCrossRef
20.
Devarbhavi H, Joseph T, Sunil Kumar N, et al. The Indian network of drug-induced liver injury: etiology, clinical features, outcome and prognostic markers in 1288 patients. J Clin Exp Hepatol. 2021;11:288–298PubMedCrossRef
21.
Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148(7):1340–1352PubMedCrossRef
22.
Hoofnagle JH, Björnsson ES. Drug-induced liver injury—types and phenotypes. N Engl J Med. 2019;381:264–273PubMedCrossRef
23.
Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806–815PubMedCrossRef
24.
25.
Kleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014;59:661–670PubMedCrossRef
26.
EASL Clinical Practice Guidelines. Drug-induced liver injury. J Hepatol. 2019;70:1222–1261CrossRef
27.
Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2021;116:878–898PubMedCrossRef
28.
Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008;47:2003–2009PubMedCrossRef
29.
Carrascosa MF, Salcines-Caviedes JR, Lucena MI, Andrade RJ. Acute liver failure following atorvastatin dose escalation: is there a threshold dose for idiosyncratic hepatotoxicity? J Hepatol. 2015;62:751–752PubMedCrossRef
30.
Hughes JD, Blagg J, Price DA, et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett. 2008;18:4872–4875PubMedCrossRef
31.
Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology. 2013;58:388–396PubMedCrossRef
32.
Aleo MD, Luo Y, Swiss R, Bonin PD, Potter DM, Will Y. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology. 2014;60:1015–1022PubMedCrossRef
33.
Tazuma S. Cyclosporin A and cholestasis: Its mechanism(s) and clinical relevancy. Hepatol Res. 2006;34:135–136PubMedCrossRef
34.
Morgan RE, Trauner M, van Staden CJ, et al. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010;118:485–500PubMedCrossRef
35.
Yu K, Geng X, Chen M, et al. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. Drug Metab Dispos. 2014;42:744–750PubMedCrossRef
36.
Zhuang X, Li L, Liu T, et al. Mechanisms of isoniazid and rifampicin-induced liver injury and the effects of natural medicinal ingredients: a review. Front Pharmacol. 2022;13:1037814PubMedPubMedCentralCrossRef
37.
38.
Lucena MI, Sanabria J, García-Cortes M, Stephens C, Andrade RJ. Drug-induced liver injury in older people. Lancet Gastroenterol Hepatol. 2020;5:862–874PubMedCrossRef
39.
Gaude GS, Chaudhury A, Hattiholi J. Drug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients. J Fam Med Prim Care. 2015;4:238–243CrossRef
40.
Weersink RA, Alvarez-Alvarez I, Medina-Cáliz I, et al. Clinical characteristics and outcome of drug-induced liver injury in the older patients: from the young-old to the oldest-old. Clin Pharmacol Ther. 2021;109:1147–1158PubMedCrossRef
41.
Andrade RJ, Aithal GP, de Boer YS, et al. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): an expert opinion meeting report. J Hepatol. 2023;79:853–866PubMedPubMedCentralCrossRef
42.
Dakhoul L, Ghabril M, Gu J, Navarro V, Chalasani N, Serrano J. Heavy consumption of alcohol is not associated with worse outcomes in patients with idiosyncratic drug-induced liver injury compared to non-drinkers. Clin Gastroenterol Hepatol. 2018;16:722–729PubMedPubMedCentralCrossRef
43.
Kunelis CT, Peters JL, Edmondson HA. Fatty liver of pregnancy and its relationship to tetracycline therapy. Am J Med. 1965;38:359–377PubMedCrossRef
44.
Bruno S, Maisonneuve P, Castellana P, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ. 2005;330:932PubMedPubMedCentralCrossRef
45.
Rosenberg P, Urwitz H, Johannesson A, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol. 2007;46:1111–1118PubMedCrossRef
46.
Stephens C, Lucena MI, Andrade RJ. Genetic risk factors in the development of idiosyncratic drug-induced liver injury. Expert Opin Drug Metab Toxicol. 2021;17:153–169PubMedCrossRef
47.
Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103–141PubMedCrossRef
48.
Cirulli ET, Nicoletti P, Abramson K, et al. A missense variant in PTPN22 is a risk factor for drug-induced liver injury. Gastroenterology. 2019;156(6):1707–1716PubMedCrossRef
49.
Devarbhavi H, Kurien SS, Raj S, et al. Idiosyncratic drug-induced liver injury associated with and without drug reaction with eosinophilia and systemic symptoms. Am J Gastroenterol. 2022;117:1709–1713PubMedCrossRef
50.
Huang Y-S, Wu C-Y, Chang T-T, et al. Drug-induced liver injury associated with severe cutaneous adverse drug reactions: a nationwide study in Taiwan. Liver Int. 2021;41:2671–2680PubMedCrossRef
51.
52.
53.
54.
Tian Q-J, Zhao X-Y, Wang Y, et al. Histologic pattern is better correlated with clinical outcomes than biochemical classification in patients with drug-induced liver injury. Mod Pathol. 2019;32:1795–1805PubMedCrossRef
55.
García-Cortés M, Lucena MI, Pachkoria K, Borraz Y, Hidalgo R, Andrade RJ. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther. 2008;27:780–789PubMedCrossRef
56.
Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, De La Cuesta FS. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001;33:123–130PubMedCrossRef
57.
Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323–1330PubMedCrossRef
58.
59.
Devarbhavi H, Aithal G, Treeprasertsuk S, et al. Drug-induced liver injury: Asia Pacific Association of Study of liver consensus guidelines. Hepatol Int. 2021;15:258–282PubMedCrossRef
60.
Hayashi PH, Lucena MI, Fontana RJ, et al. A revised electronic version of RUCAM for the diagnosis of DILI. Hepatology. 2022;76:18–31PubMedCrossRef
61.
Hayashi PH, Lucena MI, Fontana RJ. RECAM: a new and improved, computerized causality assessment tool for DILI diagnosis. Am J Gastroenterol. 2022;117:1387–1389PubMedCrossRef
62.
Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel–Uclaf causality assessment method. Hepatology. 2010;51:2117–2126PubMedCrossRef
63.
Hunt CM, Papay JI, Stanulovic V, Regev A. Drug rechallenge following drug-induced liver injury. Hepatology. 2017;66:646–654PubMedCrossRef
64.
Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42:481–489PubMedCrossRef
65.
Wang Y, Zou C, Wee A, et al. Comparison of the prognostic models for mortality in idiosyncratic drug-induced liver injury. Hepatol Int. 2023;17:488–498PubMedCrossRef
66.
Hayashi PH, Rockey DC, Fontana RJ, et al. Death and liver transplantation within 2 years of onset of drug-induced liver injury. Hepatology. 2017;66:1275–1285PubMedCrossRef
67.
Ye J-H, Ho Y-F, On AWF, et al. Trends in reporting drug-associated liver injuries in Taiwan: a focus on amiodarone. Int J Clin Pharm. 2018;40:911–920PubMedCrossRef
68.
Uetake H, Sugihara K, Muro K, Sunaya T, Horiuchi-Yamamoto Y, Takikawa H. Clinical features of Regorafenib-induced liver injury in Japanese patients from postmarketing experience. Clin Colorectal Cancer. 2018;17:e49–e58PubMedCrossRef
69.
Koch DG, Tillman H, Durkalski V, Lee WM, Reuben A. Development of a model to predict transplant-free survival of patients with acute liver failure. Clin Gastroenterol Hepatol. 2016;14:1199–1206PubMedPubMedCentralCrossRef
70.
71.
Ghabril M, Gu J, Yoder L, et al. Development and validation of a model consisting of comorbidity burden to calculate risk of death within 6 months for patients with suspected drug-induced liver injury. Gastroenterology. 2019;157(5):1245–1252PubMedCrossRef
72.
Wang C-Y, Deng Y, Li P, et al. Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: a large multicenter study. Hepatology. 2022;75:1373–1385PubMedCrossRef
73.
Fontana RJ, Hayashi PH, Gu J, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology. 2014;147(1):96–108PubMedCrossRef
74.
Bonkovsky HL, Kleiner DE, Gu J, et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology. 2017;65:1267–1277PubMedCrossRef
75.
76.
Ghabril M, Vuppalanchi R. Drug-induced nodular regenerative hyperplasia. Semin Liver Dis. 2014;34:240–245PubMedCrossRef
77.
78.
Medina-Caliz I, Robles-Diaz M, Garcia-Muñoz B, et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J Hepatol. 2016;65:532–542PubMedPubMedCentralCrossRef
79.
Fontana RJ, Hayashi PH, Barnhart H, et al. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. Am J Gastroenterol. 2015;110:1450–1459PubMedPubMedCentralCrossRef
80.
Crespo G, Fernández-Varo G, Mariño Z, et al. ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study. J Hepatol. 2012;57:281–287PubMedCrossRef
81.
82.
Fontana RJ, Liou I, Reuben A, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023;77:1036–1065PubMedCrossRef
83.
Björnsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51:2040–2048PubMedCrossRef
84.
Björnsson ES, Bergmann O, Jonasson JG, Grondal G, Gudbjornsson B, Olafsson S. Drug-induced autoimmune hepatitis: response to corticosteroids and lack of relapse after cessation of steroids. Clin Gastroenterol Hepatol. 2017;15:1635–1636PubMedCrossRef
85.
Hepatobiliary Cooperative Group of Chinese Society of Gastroenterology. Expert consensus on diagnosis and treatment of pyrrolidine alkaloids-related sinusoidal obstruction syndrome (2017, Nanjing). Zhong Hua Xiao Hua Za Zhi. 2017;513–22.
86.
Wang Z, Han H, Wang C, et al. Hepatotoxicity of pyrrolizidine alkaloid compound intermedine: comparison with other pyrrolizidine alkaloids and its toxicological mechanism. Toxins (Basel). 2021;13:849PubMedCrossRef
87.
Yang X-Q, Ye J, Li X, Li Q, Song Y-H. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes. World J Gastroenterol. 2019;25:3753–3763PubMedPubMedCentralCrossRef
88.
Chen Y, Xiong F, Wang W, et al. The long persistence of pyrrolizidine alkaloid-derived pyrrole-protein adducts in vivo: Kinetic study following multiple exposures of a pyrrolizidine alkaloid containing extract of Gynura japonica. Toxicol Lett. 2020;323:41–47PubMedCrossRef
89.
Zhuge Y, Liu Y, Xie W, Zou X, Xu J, Wang J. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. J Gastroenterol Hepatol. 2019;34:634–642PubMedCrossRef
90.
Zhang W, Liu L, Zhang M, et al. Validation of the Nanjing criteria for diagnosing pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome. J Clin Transl Hepatol. 2021;9:345–352PubMedPubMedCentral
91.
Gao H, Ruan JQ, Chen J, et al. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome. Drug Des Dev Ther. 2015;9:4861–4868CrossRef
92.
Wang X, Zhang W, Zhang M, et al. Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. Hepatol Int. 2022;16:669–679PubMedCrossRef
93.
Bonifazi F, Barbato F, Ravaioli F, et al. Diagnosis and treatment of VOD/SOS after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2020;11:489PubMedPubMedCentralCrossRef
94.
Dignan FL, Wynn RF, Hadzic N, et al. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol. 2013;163:444–457PubMedCrossRef
95.
Mohty M, Malard F, Abecassis M, et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015;50:781–789PubMedPubMedCentralCrossRef
96.
Chou C, Veracruz N, Chitnis AS, Wong RJ. Risk of drug-induced liver injury in chronic hepatitis B and tuberculosis co-infection: a systematic review and meta-analysis. J Viral Hepat. 2022;29:1107–1114PubMedCrossRef
97.
Kim WS, Lee SS, Lee CM, et al. Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. BMC Infect Dis. 2016;16:50PubMedPubMedCentralCrossRef
98.
Zheng J, Guo M-H, Peng H-W, Cai X-L, Wu Y-L, Peng X-E. The role of hepatitis B infection in anti-tuberculosis drug-induced liver injury: a meta-analysis of cohort studies. Epidemiol Infect. 2020;148: e290PubMedPubMedCentralCrossRef
99.
Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74–80PubMedCrossRef
100.
Núñez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology. 2010;52:1143–1155PubMedCrossRef
101.
Lammert C, Imler T, Teal E, Chalasani N. Patients with chronic liver disease suggestive of nonalcoholic fatty liver disease may be at higher risk for drug-induced liver injury. Clin Gastroenterol Hepatol. 2019;17:2814–2815PubMedCrossRef
102.
Liu Y-H, Guo Y, Xu H, Feng H, Chen D-Y. Impact of non-alcoholic simple fatty liver disease on antituberculosis drug-induced liver injury. Infect Drug Resist. 2021;14:3667–3671PubMedPubMedCentralCrossRef
103.
Tarantino G, Conca P, Basile V, et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res. 2007;37:410–415PubMedCrossRef
104.
Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1287–1292PubMedCrossRef
105.
Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97:77C-81CPubMedCrossRef
106.
Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007;46:1453–1463PubMedCrossRef
107.
Hoofnagle JH. Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C. J Hepatol. 2016;64:763–765PubMedCrossRef
108.
109.
Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157:1871–1876PubMedCrossRef
110.
Dakhoul L, Ghabril M, Gu J, Navarro V, Chalasani N, Serrano J. Heavy consumption of alcohol is not associated with worse outcomes in patients with idiosyncratic drug-induced liver injury compared to non-drinkers. Clin Gastroenterol Hepatol. 2018;16(5):722–729PubMedPubMedCentralCrossRef
111.
Sobhonslidsuk A, Poovorawan K, Soonthornworasiri N, Pan-Ngum W, Phaosawasdi K. The incidence, presentation, outcomes, risk of mortality and economic data of drug-induced liver injury from a national database in Thailand: a population-base study. BMC Gastroenterol. 2016;16:135PubMedPubMedCentralCrossRef
112.
Lau G, Yu M-L, Wong G, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int. 2021;15:1031–1048PubMedCrossRef
113.
Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221–244PubMedCrossRef
114.
Wang G, Duan Z. Guidelines for prevention and treatment of chronic hepatitis B. J Clin Transl Hepatol. 2021;9:769–791PubMedPubMedCentral
115.
Liu Z, Jin Q, Zhang Y, et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther. 2021;54:1134–1149PubMedPubMedCentralCrossRef
116.
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–1599PubMedCrossRef
117.
Aiso M, Takikawa H, Tsuji K, et al. Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan. Hepatol Res. 2019;49:105–110PubMedCrossRef
118.
Zhu C, Wang H, Yuan J. Clinical features of drug-induced liver injury: an analysis of 445 cases. Lin Chuang Gan Dan Bing Za Zhi. 2018;34:354–358
119.
Zhou Y, Yang L, Liao Z, He X, Zhou Y, Guo H. Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21,789 patients. Eur J Gastroenterol Hepatol. 2013;25:825–829PubMedCrossRef
120.
Huang Y-S, Chang T-T, Peng C-Y, et al. Herbal and dietary supplement-induced liver injury in Taiwan: comparison with conventional drug-induced liver injury. Hepatol Int. 2021;15:1456–1465PubMedCrossRef
121.
Philips CA, Augustine P, Rajesh S, Praveen Kumar Y, Madhu D. Complementary and alternative medicine-related drug-induced liver injury in Asia. J Clin Transl Hepatol. 2019;7:263–274PubMedPubMedCentral
122.
Philips CA, Ahamed R, Rajesh S, George T, Mohanan M, Augustine P. Comprehensive review of hepatotoxicity associated with traditional Indian Ayurvedic herbs. World J Hepatol. 2020;12:574–595PubMedPubMedCentralCrossRef
123.
Navarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury from herbals and dietary supplements in the US drug-induced liver injury network. Hepatology. 2014;60:1399–1408PubMedCrossRef
124.
Bessone F, García-Cortés M, Medina-Caliz I, et al. Herbal and dietary supplements-induced liver injury in latin America: experience from the LATINDILI network. Clin Gastroenterol Hepatol. 2022;20:e548–e563PubMedCrossRef
125.
Robles-Diaz M, Gonzalez-Jimenez A, Medina-Caliz I, et al. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Aliment Pharmacol Ther. 2015;41:116–125PubMedCrossRef
126.
Lin L, Li H, Lin H, et al. A new perspective on liver injury by traditional chinese herbs such as : the geographical area of harvest as an important contributory factor. Front Pharmacol. 2017;8:349PubMedPubMedCentralCrossRef
127.
Cui H-R, Bai Z-F, Song H-B, Jia T-Z, Wang J-B, Xiao X-H. Investigation of potential toxic factors for fleece-flower root: from perspective of processing methods evolution. Zhong Guo Zhong Yao Za Zhi. 2016;41:333–339
128.
129.
130.
Wu S-X, Sun H-F, Yang X-H, et al. “Re-evaluation upon suspected event” is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations. Zhong Guo Zhong Yao Za Zhi. 2014;39:2983–2988
131.
Tian D. Huang Di Nei Jing Su Wen. Beijing: People’s Medical Publishing House; 2005. p. 189–190
132.
133.
Song H-B, Han L. Epidemiologic characteristics, risk factors and safety evaluation of traditional Chinese medicine induced liver injury. Zhong Guo Yao Li Xue Yu Du Li Xue Za Zhi. 2016;30:291–305
134.
Medina-Caliz I, Garcia-Cortes M, Gonzalez-Jimenez A, et al. Herbal and dietary supplement-induced liver injuries in the Spanish DILI Registry. Clin Gastroenterol Hepatol. 2018;16:1495–1502PubMedCrossRef
135.
Rao A, Rule JA, Hameed B, Ganger D, Fontana RJ, Lee WM. Secular trends in severe idiosyncratic drug-induced liver injury in North America: an update from the acute liver failure study group registry. Am J Gastroenterol. 2022;117:617–626PubMedPubMedCentralCrossRef
136.
China State Drug Administration. Technical guidelines for clinical evaluation of liver injury induced by traditional Chinese medicine. Lin Chuang Gan Dan Bing Za Zhi 2018;34:1403–9
137.
Chinese society for tuberculosis. Guidelines for anti-tuberculosis drug-induced liver injury (2019 version). Zhong Hua Jie He He Hu Xi Za Zhi. 2019;42:343–56
138.
Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol. 2010;105:2396–2404PubMedCrossRef
139.
Devarbhavi H, Choudhury AK, Sharma MK, et al. Drug-induced acute-on-chronic liver failure in Asian Patients. Am J Gastroenterol. 2019;114:929–937PubMedCrossRef
140.
Nicoletti P, Devarbhavi H, Goel A, et al. Genetic risk factors in drug-induced liver injury due to isoniazid-containing antituberculosis drug regimens. Clin Pharmacol Ther. 2021;109:1125–1135PubMedCrossRef
141.
Devarbhavi H, Singh R, Patil M, Sheth K, Adarsh CK, Balaraju G. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury. J Gastroenterol Hepatol. 2013;28:161–167PubMedCrossRef
142.
Abbara A, Chitty S, Roe JK, et al. Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. BMC Infect Dis. 2017;17:231PubMedPubMedCentralCrossRef
143.
Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63:e147–e195PubMedPubMedCentralCrossRef
144.
Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–957PubMedCrossRef
145.
Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–128PubMedCrossRef
146.
Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–2388PubMedCrossRef
147.
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–246PubMedCrossRef
148.
Wu Y-L, Zhou C, Hu C-P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213–222PubMedCrossRef
149.
Shi YK, Wang L, Han BH, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol. 2017;28:2443–2450PubMedCrossRef
150.
Zhao Q, Wu ZE, Li B, Li F. Recent advances in metabolism and toxicity of tyrosine kinase inhibitors. Pharmacol Ther. 2022;237: 108256PubMedCrossRef
151.
Coutré SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56:2779–2786PubMedPubMedCentralCrossRef
152.
Peeraphatdit TB, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology. 2020;72:315–329PubMedCrossRef
153.
Lei XH, Tang YY, Li J, Mao YM. Hepatotoxicity associated with tumor immune checkpoint inhibitors. (Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi) Chin J Hepatol. 2020;28:175–178
154.
Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int. 2018;38:976–987PubMedCrossRef
155.
De Martin E, Michot J-M, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018;68:1181–1190PubMedCrossRef
156.
Yildirim S, Deniz K, Doğan E, Başkol M, Gürsoy Ş, Özkan M. Ipilimumab-associated cholestatic hepatitis: a case report and literature review. Melanoma Res. 2017;27:380–382PubMedCrossRef
157.
LoPiccolo J, Brener MI, Oshima K, Lipson EJ, Hamilton JP. Nodular regenerative hyperplasia associated with immune checkpoint blockade. Hepatology. 2018;68:2431–2433PubMedCrossRef
158.
Huffman BM, Kottschade LA, Kamath PS, Markovic SN. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management. Am J Clin Oncol. 2018;41:760–765PubMedCrossRef
159.
160.
161.
162.
163.
164.
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–168PubMedCrossRef
165.
Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2:234–240PubMedCrossRef
166.
Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28:368–376PubMedCrossRef
167.
Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med. 2018;168:121–130PubMedCrossRef
168.
Li M, Wong D, Vogel AS, et al. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. Hepatology. 2022;75:531–540PubMedCrossRef
169.
Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217–1238PubMedCrossRef
170.
Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073–4126PubMedCrossRef
171.
Ziemer M, Koukoulioti E, Beyer S, Simon JC, Berg T. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Hepatol. 2017;66:657–659PubMedCrossRef
172.
Omori G, Takada K, Murase K, et al. Successful mycophenolate mofetil treatment of a patient with severe steroid-refractory hepatitis evoked by nivolumab plus ipilimumab treatment for relapsed bladder cancer. Clin Case Rep. 2021;9:654–659PubMedCrossRef
173.
174.
Dear JW, Clarke JI, Francis B, et al. Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies. Lancet Gastroenterol Hepatol. 2018;3:104–113PubMedCrossRef
175.
McGill MR, Staggs VS, Sharpe MR, Lee WM, Jaeschke H. Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in acetaminophen overdose patients with poor outcome. Hepatology. 2014;60:1336–1345PubMedCrossRef
176.
Clarke JI, Dear JW, Antoine DJ. Recent advances in biomarkers and therapeutic interventions for hepatic drug safety—false dawn or new horizon? Expert Opin Drug Saf. 2016;15:625–634PubMedCrossRef
177.
Church RJ, Kullak-Ublick GA, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort. Hepatology. 2019;69:760–773PubMedCrossRef
178.
Li C, Rao T, Chen X, et al. HLA-B*35:01 allele is a potential biomarker for predicting polygonum multiflorum-induced liver injury in humans. Hepatology. 2019;70:346–357PubMedCrossRef
179.
Tu C, Niu M, Wei A-W, et al. Susceptibility-related cytokine panel for prediction of polygonum multiflorum-induced hepatotoxicity in humans. J Inflamm Res. 2021;14:645–655PubMedPubMedCentralCrossRef
180.
Zhang L, Niu M, Wei A-W, et al. Risk profiling using metabolomic characteristics for susceptible individuals of drug-induced liver injury caused by polygonum multiflorum. Arch Toxicol. 2020;94:245–256PubMedCrossRef
181.
Roth SE, Avigan MI, Bourdet D, et al. Next-generation DILI biomarkers: prioritization of biomarkers for qualification and best practices for biospecimen collection in drug development. Clin Pharmacol Ther. 2020;107:333–346PubMedCrossRef
182.
183.
184.
185.
Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137:3CrossRef
186.
Squires RH, Dhawan A, Alonso E, et al. Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial. Hepatology. 2013;57:1542–1549PubMedCrossRef
187.
Hu PF, Wang PQ, Chen H, et al. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury. J Dig Dis. 2016;17:618–627PubMedCrossRef
188.
189.
Wree A, Dechêne A, Herzer K, et al. Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury. Digestion. 2011;84:54–59PubMedCrossRef
190.
Wang J-B, Huang A, Wang Y, et al. Corticosteroid plus glycyrrhizin therapy for chronic drug- or herb-induced liver injury achieves biochemical and histological improvements: a randomised open-label trial. Aliment Pharmacol Ther. 2022;55:1297–1310PubMedCrossRef
191.
Niu H, Ma J, Medina-Caliz I, et al. Potential benefit and lack of serious risk from corticosteroids in drug-induced liver injury: an international, multicentre, propensity score-matched analysis. Aliment Pharmacol Ther. 2023;57:886–896PubMedCrossRef
192.
Ma J, Gu J, Lammert C. Characterization of steroid therapy for drug-induced liver injury. Gastroenterology. 2020;158:S-1304CrossRef
193.
Wan Y-M, Wu J-F, Li Y-H, Wu H-M, Wu X-N, Xu Y. Prednisone is not beneficial for the treatment of severe drug-induced liver injury: an observational study (STROBE compliant). Medicine (Baltimore). 2019;98: e15886PubMedCrossRef
194.
Wang Y, Wang Z, Gao M, et al. Efficacy and safety of magnesium isoglycyrrhizinate injection in patients with acute drug-induced liver injury: a phase II trial. Liver Int. 2019;39:2102–2111PubMedCrossRef
195.
Tang J, Gu J, Chu N, et al. Efficacy and safety of bicyclol for treating patients with idiosyncratic acute drug-induced liver injury: a multicenter, randomized, phase II trial. Liver Int. 2022;42:1803–1813PubMedCrossRef
196.
Niu H, Sanabria-Cabrera J, Alvarez-Alvarez I, et al. Prevention and management of idiosyncratic drug-induced liver injury: systematic review and meta-analysis of randomised clinical trials. Pharmacol Res. 2021;164: 105404PubMedCrossRef
197.
Yao L, Zhang J, Jin J, et al. An analysis of the efficacy and safety of compound glycyrrhizin injections in the treatment of drug-induced liver injury using a nationwide database. Int J Clin Pharm. 2022;44:731–740PubMedCrossRef
198.
Zhang B, Jiang G, Wang L, et al. An analysis of silybin meglumine tablets in the treatment of drug-induced liver injury as assessed for causality with the updated Roussel Uclaf Causality Assessment Method using a nationwide database. Br J Clin Pharmacol. 2023;89:1329–1337PubMedCrossRef
199.
Lei X, Zhang J, Xu Q, et al. Exploring the efficacy and safety of polyene phosphatidylcholine for treatment of drug-induced liver injury using the Roussel Uclaf causality assessment method: a propensity score matching comparison. J Int Med Res. 2021;49:3000605211039810PubMedCrossRef
200.
Li J, Zhang J, Xu X, et al. Hugan tablets for the treatment of RUCAM based drug-induced liver injury: a propensity score matching analysis using a nationwide database. Expert Rev Clin Pharmacol. 2021;14:1543–1550PubMedCrossRef
201.
Liu W, Chen Z, Chen J. Efficacy of liver protection of Wuling Pills in outpatient anti-tuberculosis treatment: an observational study. Zhong Xi Yi Jie He Gan Bing Za Zhi. 2012;22:122–123
202.
Li X, Zhou J, Chen S, et al. Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer. J Int Med Res. 2014;42:906–914PubMedCrossRef
203.
Chu NH, Li L, Zhang X, et al. Role of bicyclol in preventing drug-induced liver injury in tuberculosis patients with liver disease. Int J Tuberc Lung Dis. 2015;19:475–480PubMedCrossRef
204.
Yan Y, Mo Y, Zhang D. Magnesium isoglycyrrhizinate prevention of chemotherapy-induced liver damage during initial treatment of patients with gastrointestinal tumors. (Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi) Chin J Hepatol. 2015;23:204–208
205.
Li G, Chen R, Wang W. A multicenter study of magnesium isoglycyrrhizinate injection to prevent liver injury induced by chemotherapy in hematological malignancies. Shaan Xi Yi Xue Za Zhi. 2019;48:787–790
206.
Wu Y, Zhang J, Yang Y. Systematic review of efficacy and safety of magnesium lsoglycyrrhizinate in the prevention of liver injury induced by chemotherapy. Zhong Guo Yi Yuan Yong Yao Ping Jia Yu Fen Xi 2021;21:333–7
207.
Qin S, Yang L, Wang K, et al. Efficacy and safety of magnesium isoglycyrrhizinate injection to prevent chemotherapy-induced acute liver injury (MAGIC-301): a multicenter, randomized, controlled clinical study. Lin Chuang Zhong Liu Xue Za Zhi. 2017;22:97–106
208.
Chen Y, Ye P, Ren C, et al. Pharmacoeconomics of three therapeutic schemes for anti-tuberculosis therapy induced liver injury in China. Open Med (Wars). 2018;13:53–63PubMedCrossRef
209.
Leng N, Liu Y, Qiu Y, et al. Network meta-analysis of five liver protective drugs in the treatment of drug-induced liver injury. Zhong Guo Yi Yao Ke Xue. 2022;12:42–47
210.
Li T, Chen R, Li J-R, Song Q-Y, Wu B. Economic evaluation of protecting liver and lowering transaminase regimens for chronic hepatitis B with elevated ALT. Zhong Guo Yao Fang. 2013;24:4321–4324
211.
Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a US multicenter, prospective study. Hepatology. 2010;52:2065–2076PubMedCrossRef
212.
213.
Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY. l-Ornithine l-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2018;5:CD012410PubMed
214.
Schmid M, Peck-Radosavljevic M, König F, Mittermaier C, Gangl A, Ferenci P. A double-blind, randomized, placebo-controlled trial of intravenous l-ornithine-l-aspartate on postural control in patients with cirrhosis. Liver Int. 2010;30:574–582PubMedCrossRef
215.
Jain A, Sharma BC, Mahajan B, et al. l-Ornithine l-aspartate in acute treatment of severe hepatic encephalopathy: a double-blind randomized controlled trial. Hepatology. 2022;75:1194–1203PubMedCrossRef
216.
Sidhu SS, Sharma BC, Goyal O, Kishore H, Kaur N. l-Ornithine l-aspartate in bouts of overt hepatic encephalopathy. Hepatology. 2018;67:700–710PubMedCrossRef
217.
Acharya SK, Bhatia V, Sreenivas V, Khanal S, Panda SK. Efficacy of l-ornithine l-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology. 2009;136:2159–2168PubMedCrossRef
218.
Larsen FS, Schmidt LE, Bernsmeier C, et al. High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol. 2016;64:69–78PubMedCrossRef
219.
Xiong G, Yang Z, Yi J, et al. DDInter: an online drug-drug interaction database towards improving clinical decision-making and patient safety. Nucleic Acids Res. 2022;50:D1200–D1207PubMedCrossRef
220.
He N, Su S, Ye Z, et al. Evidence-based guideline for therapeutic drug monitoring of vancomycin: 2020 update by the division of therapeutic drug monitoring. Chin Pharmacol Soc Clin Infect Dis. 2020;71:S363–S371CrossRef
Metadata
Title
Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update
Authors
Yimin Mao
Shiwu Ma
Chenghai Liu
Xiaoyan Liu
Minghua Su
Dongliang Li
Yiling Li
Gongying Chen
Jun Chen
Jinjun Chen
Jingmin Zhao
Xiaoyan Guo
Jieting Tang
Yuzheng Zhuge
Qing Xie
Wen Xie
Rongtao Lai
Dachuan Cai
Qingxian Cai
Yang Zhi
Xiaoyun Li
the Technology Committee on DILI Prevention, Management, Chinese Medical Biotechnology Association; Study Group on Drug-Induced Liver Disease, Chinese Society of Hepatology, Chinese Medical Association
Publication date
24-02-2024
Publisher
Springer India
Published in
Hepatology International / Issue 2/2024
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-023-10633-7

Other articles of this Issue 2/2024

Hepatology International 2/2024 Go to the issue

Original Article

An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan

Review Article

Artificial intelligence in liver imaging: methods and applications

Original Article

Hepatocellular carcinoma (HCC) tumor microenvironment is more suppressive than colorectal cancer liver metastasis (CRLM) tumor microenvironment

Original Article

TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis

Letter to the Editor

Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated

Original Article

Preventing viral relapse with prophylactic tenofovir in hepatitis B carriers receiving chemotherapy: a phase IV randomized study in Taiwan
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits